Comprised of some of the nation’s most accomplished business leaders and distinguished academic medical researchers, the MMRC Board of Directors provides strategic and fiscal oversight to guide the Consortium’s research efforts.
Board of Directors
W Dana LaForge—Chairman
Partner Brera Capital Partners, LLC
W Dana LaForge is a Partner at Brera Capital Partners with overall responsibility for all aspects of this $680 million private equity fund. Prior to joining Brera in 2006, Mr LaForge ran Colonnade Financial Group, Inc, a private equity services firm he founded in June 1992 with the support of Deutsche Bank. At Colonnade he managed a portfolio of private equity investments owned by Deutsche Bank. Earlier in his career, Mr LaForge was a Managing Director at Deutsche Bank Alex Brown, where he headed the Financial Institutions Group in Investment Banking. While there, he primarily advised clients on merger and acquisition transactions after several years of trading mortgage-backed securities. In addition to serving on the Board of Directors of the MMRF, Mr LaForge serves on the Board of Directors of GAB Robins, NA, Residential Loss Control Holdings, Inc and Western Industries. Mr LaForge earned a BS from Washington and Lee University and an MBA from Harvard Business School. He lives in New York City with his wife, Kathleen McCabe, and their two young daughters.
Kenneth C Anderson, MD
Chief, Division of Hematologic Neoplasia Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute
Dr Kenneth Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at Johns Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome. Dr Anderson received the Waldenström’s Award from the International Myeloma Workshop in 2003, the Robert A Kyle Lifetime Achievement Award from the International Myeloma Foundation in 2005, the Joseph H Burchenal Award for Clinical Research from the American Association for Cancer Research in 2007, and the William Dameshek Prize for Outstanding Contributions to Hematology from the American Society of Hematology in 2008. He was elected into the Johns Hopkins Society of Scholars in 2009, the Institute of Medicine of the National Academy of Sciences in 2010, and the Royal College of Physicians and of Pathologists (UK) in 2010. In 2011 he received the David A Karnofsky Award from the American Society of Clinical Oncology.
Karen E Andrews
SVP, Legal and Business Affairs Hachette Book Group USA
Karen E Andrews is currently SVP, Legal and Business Affairs of Hachette Book Group USA in New York. Previously, Karen was the General Counsel and Corporate Secretary of BBDO Worldwide, Inc where she was responsible for the management of the legal activities of over 150 individual operating units throughout the world. Prior to joining BBDO Worldwide, Ms Andrews was Associate General Counsel and Director of Television Business Affairs at Time Inc, Ms Andrews began her career in law as a Litigation Associate at the New York law firm of Weil, Gotshal & Manges, where she specialized in entertainment litigation. Ms Andrews graduated cum laude from the University of Vermont with a Bachelor of Science degree in Biology and earned her law degree cum laude from Temple School of Law. Ms Andrews is a member of the American Bar Association and the New York State Bar Association. In 1998, Ms Andrews co-founded the Multiple Myeloma Research Foundation with Kathy Giusti.
William K Bowes, Jr
Founding Partner US Venture Partners
William “Bill” Bowes is a founding partner of US Venture Partners (USVP), where he led the firm’s investments in Advanced Cardiovascular Systems, Applied Biosystems, Devices for Vascular Intervention, Glycomed, Sun Microsystems, and Ventritex. Prior to founding USVP, Bowes had established himself as a successful venture capitalist with companies like Cetus, Raychem, and Dymo Industries. Previous to this, Bowes served as Senior Vice President and Director of Blyth Eastman Dillon & Company and was a consultant to Blyth Eastman Paine Webber. Bowes currently serves on the Board of the Xoma Corporation and was a founding shareholder of Amgen and its first Chairman and Treasurer. Today, Bowes is an active supporter of arts and education in the San Francisco Bay Area and interdisciplinary medical research nationwide. He currently serves on the advisory committees of Bio-X, the Institute for Systems Biology, QB3, and Harvard Partners Center for Genetics and Genomics; the executive committee of the San Francisco Conservatory of Music; and the Board of Directors of the UCSF Foundation, the Asian Art Museum, Grace Cathedral, and the Hoover Institution. He is on the visiting committee at the Harvard Business School. Bowes holds a BA in Economics from Stanford University and an MBA from Harvard University.
Frank Douglas, PhD, MD
Senior Fellow, Kauffman Foundation Partner, Pure Tech Ventures Founder, MIT Center for Biomedical Innovation
Dr Douglas advises the Kauffman Foundation as a Senior Fellow. He is also Partner of Pure Tech Ventures and Founder and first Executive Director of the MIT Center for Biomedical Innovation. At MIT, he was a professor at the Sloan School of Management and also held appointments in the departments of biology, biological engineering, and the Harvard-MIT Division of Health Sciences and Technology. Formerly, Dr Douglas was Executive Vice President, Chief Scientific Officer, and a Member of the Board of Management at Aventis. He serves on the board of directors of a number of pharmaceutical companies. Dr Douglas is the recipient of the 2007 Black History Makers Award and has been honored twice as the Global Pharmaceutical R&D Director of the Year. He has also received the Medal of Honor and an Honorary Professorship from the Johann Wolfgang von Goethe University, Frankfurt, Germany. Dr Douglas received his PhD in physical chemistry and MD from Cornell University. He did his internship and residency in internal medicine at the Johns Hopkins Medical Institution and a fellowship in neuroendocrinology at the National Institutes of Health.
Founder and Chief Executive Officer Multiple Myeloma Research Foundation (MMRF) Multiple Myeloma Research Consortium (MMRC)
Kathy Giusti is the Founder and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC). Giusti launched the MMRF in 1998, after her diagnosis with the incurable blood cancer multiple myeloma, followed by the MMRC in 2004. Leveraging her for-profit experience, she applied her business savvy to the science of cancer research and has helped to transform the culture of the traditional not-for-profit model. Her successful track record of building groundbreaking collaborative models underpinned by strong incentive structures to accelerate drug discovery and development has yielded meaningful returns for multiple myeloma patients. Further, committed to maximizing the patient-impact of these models, Giusti has shared her approach with many research organizations that are pursuing treatment advances for a number of cancers and other devastating diseases. Prior to founding the MMRF, Giusti, a former pharmaceutical executive who began her career with Merck & Co, last served as Executive Director of G.D. Searle’s worldwide arthritis franchise. Giusti, a multiple myeloma patient, was named to the 2011 TIME 100 List of the world’s most influential people. She has received many other awards for her leadership efforts, including the American Association for Cancer Research (AACR) Centennial Medal for Distinguished Public Service, the Harvard Business School Alumni Achievement Award, and the Healthcare Businesswomen's Association's Woman of the Year Award. Additionally, she has been featured on the Today Show, CBS Evening News, CBS This Morning, CNN Money, Fox News and NBC Nightly News, as well as in The Wall Street Journal, The New York Times, The Economist, and TIME. Giusti currently serves on the President's Council of Advisors on Science and Technology, as an advisor to Stand Up to Cancer, and has previously served on the President’s National Cancer Advisory Board, the Board of Directors for IMS Health, and the Institute of Medicine's National Cancer Policy Board. She received her MBA in general management from Harvard Business School and graduated from the University of Vermont magna cum laude with a Bachelor of Science in Biological Sciences.